Neuralstem to Begin Phase I Trial of Stem Cell Therapy for Spinal Cord Injury

Neuralstem, Inc is launching a Phase I safety trial of its proprietary NSI-566 stem cell therapy for treating chronic spinal cord injury (cSCI).Neuralstem has already completed Phase I studies and initiated Phase II studies of NSI-566 for treating ALS. Now that the treatment has been shown to be safe in ALS patients, and preclinical studies have demonstrated locomotor improvements following treatment in spinal cord injured rats (see Sept 2012 news story), Neuralstem is ready to tackle this second therapeutic indication. Neuralstem is conducting the trial in 8 patients at University of California, San Diego (UCSD), where much of the preclinical work was performed.

Neuralstem, Inc is launching a Phase I safety trial of its proprietary NSI-566 stem cell therapy for treating chronic spinal cord injury (cSCI).Neuralstem has already completed Phase I studies and initiated Phase II studies of NSI-566 for treating ALS. Now that the treatment has been shown to be safe in ALS patients, and preclinical studies have demonstrated locomotor improvements following treatment in spinal cord injured rats (see Sept 2012 news story), Neuralstem is ready to tackle this second therapeutic indication. Neuralstem is conducting the trial in 8 patients at University of California, San Diego (UCSD), where much of the preclinical work was performed.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail